**Proteinase Activated Receptor-3 Monoclonal Antibody**

**Stony Brook University is actively seeking companies interested in licensing the first high affinity monoclonal antibody developed against Proteinase Activated Receptor-3 (PAR3), which is instrumental in the study of its mechanism of action.**

**Technology Description:**
This is the first antibody against PAR3 and is instrumental in the study of its mechanism of action. Developed by Dr. Wadie F. Bahou, M.D., professor of Medicine and Genetics at Stony Brook University, this monoclonal antibody activates PAR3 in certain types of cells, including lymphocytes. Research laboratories can use this antibody to investigate the action and mechanism of PAR3. The antibody is also useful for selectively activating PAR3 apart from PAR1, 2, and 4. Since the expression of human PAR3 is highly restricted, cross-reactivity or cross-activation of other cell types is low.

**Applications:**
- Western blot
- ELISA
- Immunoprecipitation
- Immunofluorescence assays

**Publications:**

**Sean Boykevisch, PhD**
**Licensing Associate**
**Office of Technology Licensing & Industry Relations**
N5002 Melville Library
Stony Brook University
Stony Brook, NY 11794-3369
631-632-6952 (voice)
Sean.Boykevisch@stonybrook.edu
www.stonybrook.edu/research/otlr